Skip to main content
Year archive

Active Biotech — 2017 filings

All 33 regulatory filings released by Active Biotech (ACTI) in 2017, sourced directly from the official regulator.

33 Filings
2017 Period
2017 filings (33)
Filing Released Lang
Active Biotech provides updated information about the company's financial position
Capital/Financing Update
2017-12-20 English
Active Biotech lämnar uppdaterad information om bolagets finansiella ställning
Capital/Financing Update
2017-12-20 Swedish
Active Biotech provides updated information about the company's financial position - the company currently lacks funding to ensure its operations for the coming twelve-month period
Capital/Financing Update
2017-12-07 English
Active Biotech lämnar uppdaterad information om bolagets finansiella ställning - bolaget har i nuläget inte finansiering för verksamheten för den kommande tolvmånadersperioden
Capital/Financing Update
2017-12-07 Swedish
Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS
Earnings Release FY 2017
2017-12-01 English
Active Biotech tillkännager data från fas II-studien ARPEGGIO med laquinimod
Regulatory Filings
2017-12-01 Swedish
Active Biotechs valberedning utsedd
AGM Information
2017-11-17 Swedish
Active Biotech's election committee appointed
AGM Information
2017-11-17 English
Interim / Quarterly Report 2017
Interim / Quarterly Report 9M 2017
2017-11-09 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report 9M 2017
2017-11-09 English
Active Biotech's partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-ACTRIMS Meeting
Regulatory Filings
2017-10-19 English
Active Biotechs partner Teva presenterar nya data för laquinimod för behandling av multipel skleros på den vetenskapliga konferensen ECTRIMS-ACTRIMS
Regulatory Filings
2017-10-19 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report H1 2017
2017-08-10 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report H1 2017
2017-08-10 English
Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017
Board/Management Information
2017-06-19 English
Helén Tuvesson ny VD för Active Biotech AB från 1 juli 2017
Board/Management Information
2017-06-19 Swedish
Annual General Meeting of Active Biotech AB
AGM Information
2017-06-16 English
Årsstämma i Active Biotech AB
AGM Information
2017-06-16 Swedish
Report Publication Announcement 2017
Report Publication Announcement
2017-05-18 English
Annual Report 2017
Annual Report FY 2017
2017-05-18 Swedish
Active Biotech: Notice of Annual General Meeting of Shareholders
AGM Information
2017-05-17 English
Active Biotech: Kallelse till årsstämma
AGM Information
2017-05-17 Swedish
Teva och Active Biotech tillkännager att det primära kliniska målet i CONCERTO-studien med laquinimod i RRMS ej uppnåtts
Earnings Release FY 2017
2017-05-05 Swedish
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint
Legal Proceedings Report
2017-05-05 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2017-04-27 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2017-04-27 English
Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
Regulatory Filings
2017-04-12 English
Active Biotech: FDA beviljar särläkemedelsstatus för tasquinimod för behandling av multipelt myelom
Regulatory Filings
2017-04-12 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report FY 2016
2017-02-16 Swedish
Audit Report / Information 2016
Audit Report / Information FY 2016
2017-02-16 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-01-17 English
The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma
Regulatory Filings
2017-01-09 English
Det europeiska patentverket beviljar patent för tasquinimod för behandling av multipelt myelom
Regulatory Filings
2017-01-09 Swedish